Results 91 to 100 of about 402,161 (308)

Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the concentration of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and plasma in Alexander disease (AxD) and whether GFAP levels are predictive of disease phenotypes. Methods CSF and plasma were collected (longitudinally when available) from AxD participants and non‐AxD controls.
Amy T. Waldman, Asako Takanohashi, Joshua Y. Joung, Geraldine W. Liu, Kaley Arnold, Amy Pizzino, Walter Faig, Sarah Woidill, Sona Narula, Adeline L. Vanderver   +9 more
wiley   +1 more source

Association of Glutathione S-transferase Genes (M1 and T1) with the Risk of Acute Myeloid Leukemia in a Moroccan Population

Middle East Journal of Cancer, 2017
Background: Acute myeloid leukemia, as most cancers, results from exposure to carcinogens and an impaired inherited individual capacity to eliminate xenobiotics. The present case-control study measures the relationship between glutathione S-transferase
Ait Boujmia Oum Kaltoum, Nadifi Sellama, Dehbi Hind, Kassogue Yaya, Lamchahab Mouna, Quessar Asma   +5 more
doaj  

Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations

Haematologica, 2014
Acute myeloid leukemia is a neoplasm characterized by recurrent molecular aberrations traditionally demonstrated by cytogenetic analyses. We used high density genome-wide genotyping and gene expression profiling to reveal acquired cryptic abnormalities ...
Saman Abbas, Mathijs A. Sanders, Annelieke Zeilemaker, Wendy M.C. Geertsma-Kleinekoort, Jasper E. Koenders, Francois G. Kavelaars, Zabiollah G. Abbas, Souad Mahamoud, Isabel W.T. Chu, Remco Hoogenboezem, Justine K. Peeters, Ellen van Drunen, Janneke van Galen, H. Berna Beverloo, Bob Löwenberg, Peter J.M. Valk   +15 more
doaj   +1 more source

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]

, 2017
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival.
Al Mumma, Baron, Boztug, Boztug, Bredeson, Burroughs, Carreras, Casper, Casper, Cieri, Copelan, Dalle, Danylesko, Fichtner, Galaup, Glowka, Gupta, Gyurkocza, Kroger, Kroger, Majhail, Meinhardt, Munkelt, Nagler, Nagler, Palmer, Pel, Richardson, Rizzo, Savani, Savani, Scheulen, Schmidmaier, Schmitt, Sengsayadeth, Sengsayadeth, Shimoni, Shimoni, Slatter, ten Brink, Wachowiak, Williams   +41 more
core   +1 more source

Biomimetic Copper‐Doped Nano‐Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia

Advanced Healthcare Materials, EarlyView.
We developed a novel copper‐doped aluminum nano‐adjuvant (CuNA) to overcome cytarabine resistance in acute myeloid leukemia (AML). CuNA effectively sensitizes drug‐resistant AML cells to cytarabine by inducing mitochondrial dysfunction and inhibiting HMGCR/GPX4 to amplify ferroptosis.
Chao He, Lingxiao Zhang, Yue Xiong, Yu Wang, Yuqing Zeng, Dandan Su, Ran Wang, Ying Li, Hongbo Chen, Fang Cheng, Zhi Ping Xu   +10 more
wiley   +1 more source

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase. [PDF]

Clin Med Insights Oncol, 2022
Yohanan B, George B.
europepmc   +1 more source

Nanobody‐Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging

Advanced Healthcare Materials, EarlyView.
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan, Hyunseung Lee, Rema Naskar, Mi Young Cho, Hye Sun Park, Eun Hee Han, Soumyadip Hore, Sun Hee Cho, Truc Ngoc Kim Lam, Taewoong Son, Tae Jung Park, Inkyu Hwang, Jonathan L. Sessler, Kwan Soo Hong   +13 more
wiley   +1 more source

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML 10 and 12 trials [PDF]

, 2005
Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myelold leukemia (AML) but the most efficacious therapy for FLT3/ ITD+ patients is currently unknown.
Burnett, AK, Gale, RE, Hills, R, Kottaridis, PD, Linch, DC, Srirangan, S, Wheatley, K   +6 more
core  

The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia [PDF]

, 2013
CD56 is expressed in 15–20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis.
A Blair, A Cesano, A Vilas-Zornoza, AG Renner, Alessandro Rambaldi, Alessia Casolaro, Alice Pezzoni, B Löwenberg, B Valsasina, Barbara Valsasina, C McInnes, Clara Albanese, D Raspadori, E Di Bona, E Estey, E Radaelli, EM Lee, Enrico Pesenti, F Ravandi, FR Appelbaum, Francesco Bertolini, Francesco Marchesi, G Tsykunova, Gemma Texido, Gianni Cazzaniga, H Chang, I Beria, J Delgado, J Golay, J Suela, J Zuber, Josee Golay, JR Novontny, JW Rocco, K Strebhardt, M Bardini, Marco Losa, Martino Introna, MJ Walter, MR Baer, Nadia Amboldi, PA Greif, R Giavazzi, Rachele Alzani, Roberta Ceruti, S Gattenloehner, Sabrina Cribioli, Silvia Bungaro, T Berg, T Ikezoe, T Lapidot, TJ Ley, U Cucchi, Ursula Giussani, Veronica Patton, Z Li   +55 more
core   +3 more sources

Turning Unpredictable Biomolecule Adsorption to Controlled Corona Formation: Focus on Carbon Nanomaterials

Advanced Materials, EarlyView.
Controlling the protein corona formation onto carbon nanomaterials (CNMs) enhances their functionalities as platforms for cancer theranostics. Here, we reviewed the effects of the intrinsic and acquired properties of CNMs on protein corona formation, the consequent biological and toxicological outcomes, and the strategies to reshape corona formation ...
Yajuan Zou, Yalei Hu, Jie Yu, Naoki Komatsu, Yuta Nishina, Alberto Bianco   +5 more
wiley   +1 more source